How has been the historical performance of Jenburkt Pharma?

Answer:The historical performance of Jenburkt Pharma shows a consistent growth trend in net sales and profitability over the years.

Breakdown:
Jenburkt Pharma's net sales increased from 123.98 Cr in Mar'22 to 151.69 Cr in Mar'25, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 123.98 Cr in Mar'22 to 151.69 Cr in Mar'25. The company's operating profit (PBDIT) also saw significant growth, climbing from 32.21 Cr in Mar'22 to 47.11 Cr in Mar'25, indicating improved operational efficiency. Profit before tax rose from 29.87 Cr in Mar'22 to 43.93 Cr in Mar'25, while profit after tax increased from 22.30 Cr to 32.06 Cr during the same period. The earnings per share (EPS) demonstrated a robust increase from 48.58 in Mar'22 to 72.7 in Mar'25. On the balance sheet, total assets grew from 142.58 Cr in Mar'22 to 194.72 Cr in Mar'25, with total liabilities increasing from 142.58 Cr to 194.72 Cr, indicating a proportional rise in both assets and liabilities. The cash flow from operating activities improved significantly, reaching 27.00 Cr in Mar'25, compared to 9.00 Cr in Mar'22, showcasing enhanced cash generation capabilities. Overall, Jenburkt Pharma has demonstrated strong financial performance with consistent growth in sales, profits, and cash flow over the years.